基于肝动脉灌注化疗的肝细胞癌治疗进展
Progress in the Treatment of Hepatocellular Carcinoma Based on Hepatic Arterial Infusion Chemotherapy
摘要: 在亚洲，肝细胞癌(hepatocellular carcinoma, HCC)发病率和死亡率居恶性肿瘤前列，很多患者发现肝癌时已是中晚期，失去手术机会。对于中晚期HCC，推荐的治疗方案包括肝动脉化疗栓塞(transarterial chemoembolization, TACE)、靶向药物治疗、免疫药物治疗等，而肝动脉灌注化疗(hepatic arterial infusion chemotherapy, HAIC)亦是晚期HCC治疗方案之一。另外，HAIC的药物选择多样，没有统一的标准方案，并且基于HAIC的联合治疗方法较多，将对此作一总结，以期为临床治疗提供指导与思路。
Abstract: In Asia, the incidence and mortality of hepatocellular carcinoma (HCC) rank among the top of malignant tumors, and many patients lose the chance of surgery when their liver cancer is found at an advanced stage. For advanced HCC, the recommended treatment options include transarterial chemoembolization (TACE), targeted drug therapy and immunotherapy, etc. Hepatic arterial infusion chemotherapy (HAIC) is also one of the treatment options for advanced HCC. In addition, HAIC has a variety of drug choices without a unified standard regimen, and there are many therapy methods based on HAIC. This paper will summarize these problems, in order to provide guidance and ideas for clinical treatment.
文章引用：郭宇, 刘作金. 基于肝动脉灌注化疗的肝细胞癌治疗进展[J]. 临床医学进展, 2022, 12(1): 587-592. https://doi.org/10.12677/ACM.2022.121087

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Feng, R.-M., Zong, Y.-N., Cao, S.-M., et al. (2019) Current Cancer Situation in China: Good or Bad News from the 2018 Global Cancer Statistics? Cancer Communications (London, England), 39, 22. [Google Scholar] [CrossRef] [PubMed]
[3] Lin, T.-Y., Lee, C.-S., Chen, K.-M., et al. (1987) Role of Surgery in the Treatment of Primary Carcinoma of the Liver: A 31-Year Experience. British Journal of Surgery, 74, 839-842. [Google Scholar] [CrossRef] [PubMed]
[4] Yamashita, T. (2012) Current Status of Hepatocellular Carcinoma Treatment in Japan: Hepatic Arterial Infusion Chemotherapy. Clinical Drug Investigation, 32, 15-23. [Google Scholar] [CrossRef] 
[5] 石明, 何敏柯, 陈敏山. 肝动脉灌注化疗的现状与前景[J]. 外科理论与实践, 2020, 25(1): 10-14.
[6] Zwelling, L.A., Michaels, S., Schwartz, H., et al. (1981) DNA Cross-Linking as an Indicator of Sensitivity and Resistance of Mouse L1210 Leukemia to Cis-diamminedichloroplatinum(II) and L-phenylalanine Mustard. Cancer Research, 41, 640-649.
[7] Kondo, M., Morimoto, M., Ishii, T., et al. (2015) Hepatic Arterial Infusion Chemotherapy with Cisplatin and Sorafenib in Hepatocellular Carcinoma Patients Unresponsive to Transarterial Chemoembolization: A Propensity Score-Based Weighting. Journal of Digestive Diseases, 16, 143-151. [Google Scholar] [CrossRef] [PubMed]
[8] Takaki, H., Yamakado, K., Tsurusaki, M., et al. (2015) Hepatic Arterial Infusion Chemotherapy with Fine-Powder Cisplatin and Iodized-Oil Suspension in Patients with Intermediate-Stage and Advanced-Stage (Barcelona Clinic Liver Cancer Stage-B or Stage-C) Hepatocellular Carcinoma: Multicenter Phase-II Clinical Study. International Journal of Clinical Oncology, 20, 745-754. [Google Scholar] [CrossRef] [PubMed]
[9] Qin, S.K., Bai, Y.X., Lim, H.Y., et al. (2013) Randomized, Multicenter, Open-Label Study of Oxaliplatin plus Fluorouracil/Leucovorin versus Doxorubicin as Palliative Chemotherapy in Patients with Advanced Hepatocellular Carcinoma from Asia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 3501-3508. [Google Scholar] [CrossRef] 
[10] 李伟, 张良杰, 李冬冬, 等. 奥沙利铂联合氟尿嘧啶/亚叶酸钙方案经肝动脉灌注化疗治疗晚期肝细胞癌[J]. 泰山医学院学报, 2021, 42(1): 37-40.
[11] He, M.-K., Le, Y., Li, Q.-J., et al. (2017) Hepatic Artery Infusion Chemotherapy Using mFOLFOX versus Transarterial Chemoembolization for Massive Unresectable Hepatocellular Carcinoma: A Prospective Non-Randomized Study. Chinese Journal of Cancer, 36, 704-711. [Google Scholar] [CrossRef] [PubMed]
[12] Lyu, N., Lin, Y., Kong, Y., et al. (2018) FOXAI: A Phase II Trial Evaluating the Efficacy and Safety of Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorin for Advanced Hepatocellular Carcinoma. Gut, 67, 395-396. [Google Scholar] [CrossRef] [PubMed]
[13] 吕会来, 张丽, 温士旺, 等. 雷替曲塞联合奥沙利铂二线治疗晚期贲门癌的疗效观察[J]. 河北医科大学学报, 2016, 37(1): 24-26.
[14] Wu, D.-M., Wang, Y.-J., Fan, S.-H., et al. (2017) Network Meta-Analysis of the Efficacy of First-Line Chemotherapy Regimens in Patients with Advanced Colorectal Cancer. Oncotarget, 8, 100668-100677. [Google Scholar] [CrossRef] [PubMed]
[15] Liu, B.J., Zhu, X., Gao, S., et al. (2019) Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin Post-Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. Journal of Interventional Medicine, 2, 91-96. [Google Scholar] [CrossRef] [PubMed]
[16] Guo, J.-H., Zhang, H.-Y., Gao, S., et al. (2017) Hepatic Artery Infusion with Raltitrexed or 5-Fluorouracil for Colorectal Cancer Liver Metastasis. World Journal of Gastroenterology, 23, 1406-1411. [Google Scholar] [CrossRef] [PubMed]
[17] 艾宁, 李智岗, 王永中, 等. 雷替曲塞联合洛铂动脉灌注方案在原发性肝癌介入中的应用价值[J]. 河北医科大学学报, 2019, 40(12): 1430-1432+1454.
[18] Nagamatsu, H., Sumie, S., Niizeki, T., et al. (2016) Hepatic Arterial Infusion Chemoembolization Therapy for Advanced Hepatocellular Carcinoma: Multicenter Phase II Study. Cancer Chemotherapy and Pharmacology, 77, 243-250. [Google Scholar] [CrossRef] [PubMed]
[19] Kasai, K., Ushio, A., Kasai, Y., et al. (2011) Combination Therapy of Intra-Arterial 5-Fluorouracil and Systemic Pegylated Interferon α-2b for Advanced Hepatocellular Carcinoma. International Journal of Clinical Oncology, 16, 221-229. [Google Scholar] [CrossRef] [PubMed]
[20] Kasai, K., Kooka, Y., Suzuki, Y., et al. (2014) Efficacy of Hepatic Arterial Infusion Chemotherapy Using 5-Fluorouracil and Systemic Pegylated Interferon α-2b for Advanced Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 21, 3638-3645. [Google Scholar] [CrossRef] [PubMed]
[21] Nouso, K., Miyahara, K., Uchida, D., et al. (2013) Effect of Hepatic Arterial Infusion Chemotherapy of 5-Fluorouracil and Cisplatin for Advanced Hepatocellular Carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. British Journal of Cancer, 109, 1904-1907. [Google Scholar] [CrossRef] [PubMed]
[22] Obi, S., Sato, S. and Kawai, T. (2015) Current Status of Hepatic Arterial Infusion Chemotherapy. Liver Cancer, 4, 188-199. [Google Scholar] [CrossRef] [PubMed]
[23] Kudo, M. (2012) Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy. Liver Cancer, 1, 62-70. [Google Scholar] [CrossRef] [PubMed]
[24] Wilhelm, S.M., Carter, C., Tang, L., et al. (2004) BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Research, 64, 7099-7109. [Google Scholar] [CrossRef] 
[25] Llovet, J.M., Di Bisceglie Adrian, M., Bruix, J., et al. (2008) Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 100, 698-711. [Google Scholar] [CrossRef] [PubMed]
[26] He, M.K., Li, Q.J., Zou, R.H., et al. (2019) Sorafenib plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncology, 5, 953-960. [Google Scholar] [CrossRef] [PubMed]
[27] Nagai, H., Mukozu, T., Ogino, Y.U., et al. (2015) Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Anticancer Research, 35, 2269-2278.
[28] Hato, T., Goyal, L., Greten, T.F., et al. (2014) Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions. Hepatology (Baltimore, Md.), 60, 1776-1782. [Google Scholar] [CrossRef] [PubMed]
[29] Johnston, M.P. and Khakoo, S.I. (2019) Immunotherapy for Hepatocellular Carcinoma: Current and Future. World Journal of Gastroenterology, 25, 2977-2989. [Google Scholar] [CrossRef] [PubMed]
[30] Mei, J., Tang, Y.H., Wei, W., et al. (2021) Hepatic Arterial Infusion Chemotherapy Combined with PD-1 Inhibitors Plus Lenvatinib versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 11, Article ID: 618206. [Google Scholar] [CrossRef] [PubMed]
[31] Mei, J., Li, S.H., Li, Q.J., et al. (2021) Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 8, 167-176. [Google Scholar] [CrossRef] 

为你推荐